Form 4: Aquestive Therapeutics Director Receives Stock Options

Director Marco Taglietti was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a compensation arrangement.

Summary

• Director Marco Taglietti received a grant of 50,500 stock options on June 10, 2026.
• The options have an exercise price of $3.99 per share.
• The options are scheduled to vest in full on June 10, 2027, contingent upon continuous service.
• The options have an expiration date of June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation grant.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of time-based vesting (one-year cliff) is consistent with standard director compensation packages for mid-cap pharmaceutical companies.
• The grant size is typical for non-executive director compensation in the biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 10, 2027.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Stock Options, Director Compensation, Insider Transaction